Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche has received European marketing approval for its once weekly injection of NeoRecormon for the treatment of anemia in patients with cancer.
Subscribe to our email newsletter
According to Roche the expansion of the product label provides benefits for the patients as they will no longer have the burden of three injections per week. Anemia affects up to 95% of cancer patients receiving chemotherapy.
Key supportive data for the new label came from a study, which was conducted in women with breast cancer receiving chemotherapy and the study conducted in patients with a wide range of cancer types also receiving chemotherapy.
NeoRecormon once weekly has been proven to effectively and rapidly correct anemia irrespective of the type of chemotherapy patients receive. It also reduces the need for blood transfusions by at least 50% compared to standard care and has been shown to significantly increase the time until patients need a first transfusion. Patients treated with NeoRecormon often experience an improvement in their quality of life and an increase in their daily energy levels.